Skip to main content
. 2022 Jun 18;158(11):509–518. doi: 10.1016/j.medcle.2021.06.023

Table 5.

Secondary outcomes at 7-day follow up from tocilizumab administration.

Outcome – no. (%) Patients
Vasopressor therapy 15 (18.3%)
Acute respiratory distress syndrome 45 (54.9%)
Respiratory failure 62 (75.6%)
Acute kidney injury 9 (10.9%)
Cardiac failure 1 (1.2%)
Septic shock 1 (1.2%)
Concomitant infection 1 (1.2%)